MicroPort Scientific Corporation (00853.HK) has issued a profit warning, expecting to report a net loss for the interim period.

According to the report from Zhito Finance APP, MicroPort Medical (00853.HK) announced that the performance of the group for the six months ending June 30, 2026, is expected as follows: The revenue from the group's continuing operations is projected to grow by approximately 12% to 14% year-on-year, with the overseas business continuing to contribute a strong growth of about 140%; the profitability at the operational level of the group is steadily improving, with the gross margin of continuing operations expected to increase by approximately 3 to 4 percentage points year-on-year, while continuing to promote refined operations and cost control. During the period, the continuing operations are expected to achieve an operating net profit of no less than 24 million US dollars (for the six months ending June 30, 2025, the continuing operations reported an operating net loss of 413 million US dollars); however, due to financial costs incurred during the period of approximately 43 million US dollars, as well as revaluations of convertible loans, exchange rate fluctuations, and one-time losses from certain asset impairments and transactions, it is expected that the group will incur a net loss from continuing operations not exceeding 50 million US dollars (for the six months ending June 30, 2025, the net loss from continuing operations was 49 million US dollars).